

February 7, 2026

To,
BSE Limited
Corporate Relationship Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001.

Scrip Code: 531015

Subject: Submission of Unaudited Standalone Financial Results along with Auditors' Report for the quarter ended December 31, 2025

Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are attaching herewith the Un-audited Standalone Financial Results along with Limited Review Report of the Statutory Auditors of the company, PPKG & Co Chartered Accountants for the quarter and nine months ended December 31, 2025.

The Financial Results are also available on the website of the Company at www.venmaxdrugs.com and on the website of BSE www.bseindia.com.

The Board Meeting commenced at 04:00 PM and concluded at 05:30 PM.

Kindly take the above information on record and oblige.

Thanking You

Yours Faithfully

for **Venmax Drugs & Pharmaceuticals Limited**

Venkata Rao Sadhanala
Whole Time Director
DIN: 02906370

Reg Office: Sy. No. 115, Brig Sayeed Road, Hanumanji Colony, Bowenpally, Picket, Hyderabad – 500009
CIN: L24230TG1988PLC009102 GSTIN: 36AAACY1073C3ZM

E-mail: venmaxdrugs@gmail.com

Statement of Financial Results for the Quarter and Nine Months ended 31st December 2025

(Rs. In Lakhs)

	Particulars	Quarter ended			Nine Months ended		Year Ended
		31/12/2025 (unaudited)	30/09/2025 (unaudited)	31/12/2024 (unaudited)	31/12/2025 (unaudited)	31/12/2024 (unaudited)	31/03/2025 (Audited)
	Income						
I	Revenue from operations	155.23	131.85	19.92	408.10	47.44	80.73
II	Other income	6.83	-	-	6.83	3.00	105.32
	Total Revenue (I+II)	162.06	131.85	19.92	414.93	50.44	186.05
II	Expenses						
	Cost of materials consumed	-	-	-	-	-	-
	Purchases of Stock-in-Trade	145.29	258.41	21.67	515.95	51.94	85.21
	Change of Inventory	(4.25)	(143.97)	-	(151.40)	-	(5.75)
	Employee benefits expense	3.47	6.12	1.05	14.24	1.40	4.00
	Finance costs	0.00	0.06	0.00	0.08	0.08	0.08
	Depreciation and amortization expense	0.10	0.10	0.16	0.30	0.48	0.64
	Other expenses	13.15	6.61	46.58	23.22	75.45	103.28
	Total expenses	157.76	127.33	69.46	402.38	129.35	187.46
III	Profit before Exceptional items and tax	4.29	4.52	(49.54)	12.55	(78.90)	(1.41)
	Exceptional Items						
	Profit / (Loss) before tax	4.29	4.52	(49.54)	12.55	(78.90)	(1.41)
IV	Tax expense:						
	Current tax	1.08	2.08	-	3.16	-	-
	Deferred tax	(0.00)	(0.003)	(0.020)	(0.00)	(0.01)	(0.357)
	Profit/(loss) for the period from continuing operations	1.08	2.08	(0.02)	3.16	(0.01)	(0.36)
	Profit/(loss) from discontinued operations						
	Tax expense of discontinued operations						
	Profit/(loss) from Discontinued operations (After tax)						
V	Profit/(loss) for the year	3.21	2.44	(49.52)	9.39	(78.89)	(1.05)
	Other Comprehensive Income						

	A (i) Items that will not be reclassified to Profit or Loss (ii) Income tax relating to items that will not be reclassified to Profit or Loss B (i) Items that will be reclassified to Profit or Loss (ii) Income tax relating to items that will be reclassified to Profit or Loss Total Comprehensive Incoe for the period (Comprising Profit / (Loss)) and Other Comprehensive Income for the period)						
VI	Earnings per Equity Share - Basic and Diluted	0.05	0.03	(0.95)	0.14	(1.51)	(0.02)

Notes to Accounts:

1. The above unaudited financial results of VENMAX DRUGS AND PHARMACEUTICALS LIMITED for the Quarter and Nine Months ended 31st December 2025 as reviewed and recommended by the Audit Committee and approved by the Board of Directors at its meeting held on 7th February 2026. The Statutory Auditors of the Company have carried out a Limited Review on standalone financial results and expressed an unmodified conclusion thereon.
2. The Financial results have been prepared in accordance with applicable accounting standards prescribed under Section 133 of the Companies Act, 2013 read with (Indian Accounting Standard) Rules, 20105 (Ind AS), and other accounting principles generally accepted in India and guidelines issued by Securities and Exchange Board of India (SEBI).
3. The Company operates in single segment. Accordingly, disclosures under Indian Accounting Standards (Ind AS) 108 on operating segments are not applicable to the Company.
4. Previous period figures have been reclassified and regrouped wherever considered necessary to confirm to the current period figures.
5. During the Quarter and Nine Months period the company converted 27,69,000 share warrants in to Equity at a Face value of Rs.10 and at a premium of Rs.10/- each.

Place: Hyderabad
Date: 7th February 2026

For Venmax Drugs and Pharmaceuticals Limited

Venkata Rao Sadhanala
Whole Time Director
DIN: 02906370

Statement of Assets and Liabilities as at 31st December 2025

(Rs. In Lakhs)

Particulars	Notes	As at 31st December 2025, Unaudited	As at 31st March 2025, Audited
I.ASSETS			
(1) Non-Current Assets			
(a) Property, Plant and Equipment	3	3.75	4.05
(b) Capital Work-In-Progress			
(c) Intangible Assets			
(d) Financial Assets			
(i) Non-Current Investments			
(ii) Trade and Other Receivables			
(iii) Long Term Loans and Advances			
(d) Deferred Tax Assets (Net)			
(e) Other Non-Current Assets			
Non-Current Assets		3.75	4.05
(2) Current Assets			
(a) Inventories	4	157.15	5.75
(b) Financial Assets			
(i) Investments			
(ii) Trade and Other Receivables	5	528.90	95.26
(iii) Cash and Cash Equivalents	6	143.18	248.24
(iv) Short Term Loans and Advances	7	584.64	161.00
(c) Other Current Assets	8	528.75	2.67
Current Assets		1942.62	512.91
Total Assets		1946.37	516.96
I. EQUITY AND LIABILITIES			
(1) Equity			
(a) Share Capital	9	800.79	523.89
(b) Other Equity	10	142.64	(82.70)
Equity		943.44	441.19
(2) Non-Current Liabilities			
(a) Financial Liabilities			
(i) Long Term Borrowings			

(b) Provisions			
(c) Deferred Tax Liabilities (Net)	11	0.10	0.10
(d) Other Non-current Liabilities			
Non-Current Liabilities		0.10	0.10
(3) Current Liabilities			
(a) Financial Liabilities			
- Short term Borrowings	12	332.53	4.96
-Other Financial Liabilities			
(i) Trade Payables			
Micro and small enterprises			
Other than micro and small enterprises	13	658.87	62.87
(b) Short Term Provisions		3.91	0.70
(c) Other Current Liabilities	14	7.52	7.14
Current Liabilities		1002.83	75.67
Total Liabilities		1946.37	516.96

Place: Hyderabad
Date: 7th February 2026

For Venmax Drugs and Pharmaceuticals Limited

Venkata Rao Sadhanala
Whole Time Director
DIN: 02906370

Cash Flow Statement for the Nine Months Ended 31st December 2025

(Rs. In Lakhs)

PARTICULARS	As at 31st Dec 2025	As at Mar 31, 2025
	Unaudited	Audited
A) CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit as per Profit & Loss A/c	12.55	(1.41)
Adjustment for:		
Depreciation	0.30	0.64
Other comprehensive income	-	-
Loss on Sale / Discard of Intangible Assets (Net)		1.89
Net Operating Profit Before Working Capital	12.85	1.12
Changes		
Adjustment for:		
Trade & Other Receivables	(433.64)	(95.26)
Changes in inventory	(151.40)	(5.75)
Other Current Assets	(526.08)	(1.36)
Trade Payables	596.00	52.53
Other Financial liabilities	0.00	(10.82)
Other current liabilities	0.38	(6.94)
Provisions	3.21	(1.54)
Short Term Loans and Advances	(423.64)	(161.00)
Net Cash from Operating Activities	(922.33)	(229.02)
Direct taxes paid	3.15	-
Net Cash from Operating Activities	(925.48)	(229.02)
B) CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of Fixed Assets	-	-
Sale of Fixed assets	-	-
Net Cash from Investing Activites	-	-
C) CASH FLOW FROM FINANCING ACTIVITIES		
Share application money pending allotment	497.85	507.26
Share Application money pending allotment money returned	(5.00)	-

Proceeds from long/short term borrowings	327.57	(30.25)
Repayment of borrowings		
Net Cash from Financing Activities	820.42	477.01
Net Increase in Cash & Cash Equivalents	(105.06)	247.99
Add: Opening Cash & Cash Equivalents	248.24	0.25
Cash and Cash equivalents at the end of the year	143.18	248.24

Place: Hyderabad
Date: 7th February 2026

For Venmax Drugs and Pharmaceuticals Limited

Venkata Rao Sadhanala
Whole Time Director
DIN: 02906370

Independent Auditor's Limited Review Report on the Quarterly Unaudited Financial Results of The Company Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To,
The Board of Directors,
Venmax Drugs and Pharmaceuticals Limited
Hyderabad

We have reviewed the accompanying Statement of unaudited financial results of Venmax Drugs and Pharmaceuticals Limited (the "Company") for the quarter and nine months ended December 31st, 2025 (the "Statement") attached herewith, being submitted by the Company, pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended (the Listing Regulations").

This statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant issued there under and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed necessary procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.



Based on our review conducted as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For PPKG And CO
Chartered Accountants
FRN: 009655S

Girdhari Lal Toshniwal

GIRDHARI LAL TOSHNIWAL
(Partner)
M.No-205140



UDIN No: 26205140DWKSIK5811

Place: Hyderabad
Date: 07/02/2026